These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer. Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615 [TBL] [Abstract][Full Text] [Related]
25. Recent advances in canonical versus non-canonical Ca Cauwelier C; de Ridder I; Bultynck G Biochim Biophys Acta Mol Cell Res; 2024 Jun; 1871(5):119713. PubMed ID: 38521468 [TBL] [Abstract][Full Text] [Related]
26. The type 2 inositol 1,4,5-trisphosphate receptor, emerging functions for an intriguing Ca²⁺-release channel. Vervloessem T; Yule DI; Bultynck G; Parys JB Biochim Biophys Acta; 2015 Sep; 1853(9):1992-2005. PubMed ID: 25499268 [TBL] [Abstract][Full Text] [Related]
29. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP Ivanova H; Luyten T; Decrock E; Vervliet T; Leybaert L; Parys JB; Bultynck G Cell Calcium; 2017 Mar; 62():41-46. PubMed ID: 28179071 [TBL] [Abstract][Full Text] [Related]
30. Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP Distelhorst CW; Bootman MD Cold Spring Harb Perspect Biol; 2019 Sep; 11(9):. PubMed ID: 31110129 [TBL] [Abstract][Full Text] [Related]
32. Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling. Rys RN; Wever CM; Geoffrion D; Goncalves C; Ghassemian A; Brailovski E; Ryan J; Stoica L; Hébert J; Petrogiannis-Haliotis T; Dmitrienko S; Frenkiel S; Staiger A; Ott G; Steidl C; Scott DW; Sesques P; Del Rincon S; Mann KK; Letai A; Johnson NA Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33670870 [TBL] [Abstract][Full Text] [Related]
33. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817 [TBL] [Abstract][Full Text] [Related]
34. Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor. Monaco G; Decrock E; Nuyts K; Wagner LE; Luyten T; Strelkov SV; Missiaen L; De Borggraeve WM; Leybaert L; Yule DI; De Smedt H; Parys JB; Bultynck G PLoS One; 2013; 8(8):e73386. PubMed ID: 24137498 [TBL] [Abstract][Full Text] [Related]
35. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420 [TBL] [Abstract][Full Text] [Related]
36. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Reed JC; Zha H; Aime-Sempe C; Takayama S; Wang HG Adv Exp Med Biol; 1996; 406():99-112. PubMed ID: 8910675 [TBL] [Abstract][Full Text] [Related]
37. Small-molecule inhibitors of Bcl-2 family proteins are able to induce tumor regression in a mouse model of pre-B-cell acute lymphocytic lymphoma. Turner BC; Eves T; Refaeli Y DNA Cell Biol; 2008 Mar; 27(3):133-42. PubMed ID: 18163880 [TBL] [Abstract][Full Text] [Related]
38. Anti-apoptotic Bcl-XL protein in complex with BH3 peptides of pro-apoptotic Bak, Bad, and Bim proteins: comparative molecular dynamics simulations. Lama D; Sankararamakrishnan R Proteins; 2008 Nov; 73(2):492-514. PubMed ID: 18452209 [TBL] [Abstract][Full Text] [Related]
39. Identifying Targetable Vulnerabilities to Circumvent or Overcome Venetoclax Resistance in Diffuse Large B-Cell Lymphoma. Adams CM; McBride A; Michener P; Shkundina I; Mitra R; An HH; Porcu P; Eischen CM Cancers (Basel); 2024 Jun; 16(11):. PubMed ID: 38893249 [TBL] [Abstract][Full Text] [Related]